{"generic":"Natamycin","drugs":["Natacyn","Natamycin"],"mono":{"0":{"id":"392600-s-0","title":"Generic Names","mono":"Natamycin"},"1":{"id":"392600-s-1","title":"Dosing and Indications","sub":[{"id":"392600-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Blepharitis - Fungal infection of eye:<\/b> 1 drop in affected eye(s) 4 to 6 times\/day<\/li><li><b>Fungal conjunctivitis:<\/b> 1 drop in affected eye(s) 4 to 6 times\/day<\/li><li><b>Fungal keratitis, Caused by susceptible organisms including Fusarium solani:<\/b> 1 drop in affected eye(s) every 1 to 2 hr for 3 to 4 days; then 1 drop 6 to 8 times daily; continue for 14 to 21 days or until resolution of active fungal keratitis<\/li><\/ul>"},{"id":"392600-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children "},{"id":"392600-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> no differences in safety and efficacy noted "},{"id":"392600-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Blepharitis - Fungal infection of eye<\/li><li>Fungal conjunctivitis<\/li><li>Fungal keratitis, Caused by susceptible organisms including Fusarium solani<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Candidal vulvovaginitis<\/li><li>Oral candidiasis<\/li><\/ul>"}]},"3":{"id":"392600-s-3","title":"Contraindications\/Warnings","sub":[{"id":"392600-s-3-9","title":"Contraindications","mono":"hypersensitivity to natamycin or any component of the product <br\/>"},{"id":"392600-s-3-10","title":"Precautions","mono":"failure of improvement of keratitis after 7 to 10 days of therapy; evaluate for microorganisms not susceptible to natamycin <br\/>"},{"id":"392600-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"392600-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"392600-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Eye irritation<br\/>"},"6":{"id":"392600-s-6","title":"Drug Name Info","sub":{"0":{"id":"392600-s-6-17","title":"US Trade Names","mono":"Natacyn<br\/>"},"2":{"id":"392600-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Polyene<\/li><\/ul>"},"3":{"id":"392600-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"392600-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"392600-s-7","title":"Mechanism Of Action","mono":"Ophthalmic: Natamycin probably exerts its antifungal effects by binding to sterols in the fungal cell membrane to produce a change in membrane permeability that allows loss of essential cellular constituents.   Following topical application, natamycin is retained in the conjunctival fornices and attains effective concentrations within the corneal stroma. Significant drug concentration is usually not attained in the intraocular fluid.  <br\/>"},"9":{"id":"392600-s-9","title":"Administration","mono":"<b>Topical application, ophthalmic<\/b><br\/>shake well before using <br\/>"},"10":{"id":"392600-s-10","title":"Monitoring","mono":"symptomatic improvement<br\/>"},"11":{"id":"392600-s-11","title":"How Supplied","mono":"<b>Natacyn<\/b><br\/>Ophthalmic Suspension: 5 %<br\/>"},"13":{"id":"392600-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient on proper ophthalmic instillation technique.<\/li><li>Tell patient to not wear contact lenses until infection resolves or until approved by healthcare professional.<\/li><\/ul>"}}}